Publicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (29)

2022

  1. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

    Nature Communications, Vol. 13, Núm. 1

2020

  1. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

    European Journal of Cancer Care, Vol. 29, Núm. 4

2019

  1. Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: An estimation of life years and disease-free life years gained since its approval

    Oncotarget, Vol. 10, Núm. 42, pp. 4321-4332

2018

  1. Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii90

2017

  1. 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial

    Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441

  2. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

  3. Critically short telomeres and toxicity of chemotherapy in early breast cancer

    Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482

2016

  1. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial

    Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1601-1610

  2. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

  3. Quality indicators to assure and improve cancer care in Spain using the delphi technique

    JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 5, pp. 553-558

  4. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy

    Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1584-1593

2015

  1. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer

    European Journal of Cancer, Vol. 51, Núm. 12, pp. 1481-1489

2014

  1. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

    The Lancet Oncology, Vol. 15, Núm. 6, pp. 640-647

  2. Trastuzumab in small tumours and in elderly women

    Cancer Treatment Reviews, Vol. 40, Núm. 1, pp. 41-47

2013

  1. Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 13, Núm. 3, pp. 381-391

  2. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study

    Journal of Clinical Oncology

2010

  1. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

    The Lancet, Vol. 375, Núm. 9712, pp. 377-384

2009

  1. Guidelines for HER2 testing in breast cancer. A national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia, Vol. 42, Núm. 1, pp. 3-16

  2. Guidelines for HER2 testing in breast cancer: A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 11, Núm. 6, pp. 363-375

  3. Nonpegylated liposomal doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-overexpressing breast cancer: A multicenter phase l/ll study

    Clinical Cancer Research, Vol. 15, Núm. 1, pp. 307-314